The U.S. Food and Drug Administration’s Center for Drug Evaluation and Research (CDER) is outlining how drug developers can streamline certain nonclinical studies by using what it calls “new approach methodologies,” or NAMs, while maintaining its primary focus on human drug safety and efficacy.
In materials published on FDA.gov, CDER describes how selected nonclinical testing requirements may be met with alternative scientific methods when those methods are considered acceptable by the agency. The documents repeatedly emphasize methodologies, scientific relevance, and safety as the key criteria for any new approach.
What CDER Is Changing
According to CDER information posted on FDA.gov, the center is identifying situations in which nonclinical studies—tests typically performed before a drug is given to people—can be streamlined if developers use validated NAMs.
Nonclinical studies usually include laboratory and animal tests designed to assess a drug’s potential toxicity and biological activity. CDER states that its goal in refining this area is not to relax standards, but to allow scientifically sound methods that may be more efficient or informative to stand in for some traditional approaches.
The agency’s description of the effort highlights two linked ideas:
- Streamlined nonclinical studies: CDER indicates that in some cases, the overall nonclinical package supporting a drug application may be reduced or reshaped if the available science supports a narrower set of studies.
- Acceptable NAMs: CDER explains that new approach methodologies can be used in place of, or alongside, traditional tests when they are shown to be relevant to human biology and reliable for decision-making.
Across the FDA.gov materials, CDER ties these concepts directly to its central mission: ensuring that drugs are both safe and effective for people.
What Are New Approach Methodologies (NAMs)?
In a separate resource on FDA.gov focused specifically on New Approach Methodologies, the agency describes NAMs as newer scientific tools or strategies that can inform safety and risk assessments. CDER notes that these may include in vitro methods (tests in cells or tissues), computational models, or other non-traditional techniques, so long as they are appropriate for the question being asked.
The FDA.gov materials stress several recurring themes:
- Methodologies and approach: The agency repeatedly refers to the importance of a clear scientific approach, meaning that NAMs must be grounded in sound methodology, not just novel technology.
- Relevance: CDER highlights that any NAM must be relevant to the human condition or endpoint it is intended to predict. That relevance is a central factor in determining whether a NAM can replace or reduce existing tests.
- Safety: Safety appears throughout the FDA descriptions as the non‑negotiable standard. CDER frames NAMs as tools that must support, not weaken, its ability to identify potential risks before a drug reaches patients.
While the agency does not present NAMs as a blanket substitute for all current nonclinical tests, it signals that, where appropriate, they can become part of the accepted toolkit regulators use to evaluate new drugs.
How Streamlining Works in Practice
CDER’s description of streamlined nonclinical studies on FDA.gov indicates that the center is looking for ways to make nonclinical programs more focused, as long as the resulting data remain sufficient to support safety and efficacy decisions.
The materials suggest several practical implications:
- Case‑by‑case decisions: CDER explains that the acceptability of a NAM or a streamlined study package depends on the specific drug and the scientific questions at stake. There is no single template that applies to every product.
- Alignment with regulatory standards: Even when using NAMs, drug developers must still meet existing safety and efficacy standards. CDER’s descriptions indicate that these methods are evaluated against the same regulatory expectations as traditional tests.
- Integration, not just replacement: The FDA.gov resources describe NAMs as potential components of a broader evidence package. In some cases, they may complement rather than fully replace traditional nonclinical studies.
The agency’s language underscores that any streamlining must be justified scientifically. CDER positions itself as open to new methods but firm about the need for data that can reliably inform regulatory decisions.
Why This Matters for Patients and Developers
CDER’s public materials frame these developments within its overarching responsibility: protecting public health by ensuring that human drugs are safe and effective.
For patients and health care providers, the key point is that CDER is not changing the standard of safety it expects, but clarifying how newer scientific tools can be used to meet that standard. The agency’s emphasis on relevance and safety in its discussion of NAMs signals that it views these methods as a way to refine decision‑making, not to lower the bar.
For drug developers, CDER’s explanations on FDA.gov provide a clearer picture of when and how alternative methodologies may be acceptable. By describing streamlined nonclinical studies and acceptable NAMs in the same context, the agency is indicating that:
- Developers who can demonstrate that a NAM is methodologically sound, relevant to human outcomes, and protective of safety may be able to adjust their nonclinical programs accordingly.
- Any such adjustments must be grounded in evidence that CDER finds persuasive for regulatory purposes.
Across both FDA.gov sources, the repeated focus on methodologies, approach, relevance, and safety shows how CDER is framing this evolution: not as a departure from its core mission, but as an attempt to apply that mission using the best available science.
What to Watch Next
CDER’s materials on streamlined nonclinical studies and NAMs present a framework rather than a single, one‑time change. The agency is signaling that it will consider new methodologies as they emerge, evaluating each against its standards for scientific relevance and safety.
For readers, the central takeaway is straightforward: CDER remains focused on ensuring that human drugs are safe and effective, and it is now describing more openly how new scientific approaches can fit into that process. Future updates from FDA.gov will show how often, and in what types of drug programs, NAMs and streamlined nonclinical strategies are put into practice under this framework.
